PYXS vs. IMMP, TSVT, DSGN, HOWL, ALDX, CTNM, NKTR, ME, FHTX, and VERU
Should you be buying Pyxis Oncology stock or one of its competitors? The main competitors of Pyxis Oncology include Immutep (IMMP), 2seventy bio (TSVT), Design Therapeutics (DSGN), Werewolf Therapeutics (HOWL), Aldeyra Therapeutics (ALDX), Contineum Therapeutics (CTNM), Nektar Therapeutics (NKTR), 23andMe (ME), Foghorn Therapeutics (FHTX), and Veru (VERU). These companies are all part of the "pharmaceutical preparations" industry.
Pyxis Oncology (NASDAQ:PYXS) and Immutep (NASDAQ:IMMP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends, community ranking and analyst recommendations.
Immutep received 290 more outperform votes than Pyxis Oncology when rated by MarketBeat users. However, 79.17% of users gave Pyxis Oncology an outperform vote while only 72.37% of users gave Immutep an outperform vote.
Pyxis Oncology currently has a consensus price target of $8.80, suggesting a potential upside of 107.55%. Immutep has a consensus price target of $8.50, suggesting a potential upside of 189.12%. Given Immutep's higher possible upside, analysts clearly believe Immutep is more favorable than Pyxis Oncology.
39.1% of Pyxis Oncology shares are owned by institutional investors. Comparatively, 2.3% of Immutep shares are owned by institutional investors. 8.4% of Pyxis Oncology shares are owned by company insiders. Comparatively, 3.1% of Immutep shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Immutep has higher revenue and earnings than Pyxis Oncology.
Immutep's return on equity of 0.00% beat Pyxis Oncology's return on equity.
In the previous week, Pyxis Oncology had 3 more articles in the media than Immutep. MarketBeat recorded 6 mentions for Pyxis Oncology and 3 mentions for Immutep. Pyxis Oncology's average media sentiment score of 0.90 beat Immutep's score of 0.65 indicating that Pyxis Oncology is being referred to more favorably in the media.
Pyxis Oncology has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500. Comparatively, Immutep has a beta of 2.1, meaning that its share price is 110% more volatile than the S&P 500.
Summary
Immutep beats Pyxis Oncology on 7 of the 13 factors compared between the two stocks.
Get Pyxis Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for PYXS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PYXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pyxis Oncology Competitors List
Related Companies and Tools
